Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]

平安证券研报指出，司太立碘佛醇100ml:35g（I）规格日前获国家药监局批准。碘佛醇是碘造影剂第一 大品种，100ml:35g（I）规格占比约80%。司太立碘佛醇100ml:32g（I）规格于2023年10月获药监局批 准，2024年销售规模较小。该行认为本次主流规格获批后，公司碘佛醇销售规模有望加速放量。考虑到 碘价维持在高位，公司业绩大幅改善时点后移，该行将公司2025-2026年盈利预测下调至0.86亿、2.37亿 元（原预测为3.09亿、5.36亿元），预计2027年利润为4.13亿元。但考虑到公司原料药和制剂新增产能 释放，尤其是海外制剂认证加快推进，公司业绩改善确定性较强，维持"推荐"评级。 ...

Trading Information Summary - On August 1, 2025, the stock price of Sitai Li (603520) closed at 11.12 yuan, down 2.8%, with a turnover rate of 5.26% and a trading volume of 230,500 lots, amounting to a total transaction value of 260 million yuan [1] - The net inflow of main funds was 14.51 million yuan, accounting for 5.59% of the total transaction value, while the net inflow of speculative funds was 17.03 million yuan, accounting for 6.56% of the total transaction value. In contrast, retail investors experienced a net outflow of 31.54 million yuan, which represented 12.15% of the total transaction value [2] Company Announcement Summary - Sitai Li announced that from January 1 to July 30, 2025, it received a total of 5,111,049.20 yuan in various government subsidies. The government subsidies related to income will be included in the current profit and loss, representing 10.41% of the absolute value of the company's audited net profit for the most recent fiscal year [1][2]

Core Viewpoint - As of August 1, 2025, the stock price of Sitaili (603520) closed at 11.12 yuan, reflecting a 6.82% increase from the previous week, with the stock reaching its nearly one-year high of 11.75 yuan on July 31, 2025 [1] Company Performance - Sitaili's current total market capitalization is 4.875 billion yuan, ranking 109th out of 150 in the chemical pharmaceutical sector and 3220th out of 5149 in the A-share market [1] - The stock price fluctuated between a low of 10.41 yuan and a high of 11.75 yuan during the week [1] Government Subsidies - Sitaili announced that it received a total of 5,111,049.20 yuan in government subsidies from January 1 to July 30, 2025, which will be included in the current period's profit and loss [1] - These subsidies are related to revenue and account for 10.41% of the company's audited net profit for the most recent fiscal year [1] - The final impact on the company's 2025 profit and loss will be confirmed after the annual audit [1]

证券代码：603520 证券简称：司太立 公告编号：2025-036 浙江司太立制药股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据《企业会计准则第16号一一政府补助》的相关规定，与收益相关的政府补助5,111,049.20元将计入 当期损益。上述政府补助最终对公司2025年损益的影响将以年度审计确认后的结果为准，敬请广大投资 者注意投资风险。 特此公告。 浙江司太立制药股份有限公司董事会 重要内容提示： 2025年8月1日 ● 获得政府补助金额：5,111,049.20元 ● 对当期损益的影响：与收益相关的政府补助5,111,049.20元将计入当期损益；最终对公司2025年损益 的影响将以年度审计确认后的结果为准。 一、获得政府补助的基本情况 2025年1月1日至7月30日，浙江司太立制药股份有限公司（以下简称"公司"）及各下属子公司累计收到 各类政府补助共计5,111,049.20元。其中，与收益相关的政府补助5,111,049.20元,占公司最近一个会计年 度经审计净利润绝对值 ...

证券代码：603520 证券简称：司太立 公告编号：2025-036 浙江司太立制药股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 获得政府补助金额：5,111,049.20 元 二、政府补助的类型及对公司的影响 根据《企业会计准则第 16 号——政府补助》的相关规定，与收益相关的 政府补助 5,111,049.20 元将计入当期损益。上述政府补助最终对公司 2025 年损益的影响将以年度审计确认后的结果为准，敬请广大投资者注意投资风 险。 特此公告。 浙江司太立制药股份有限公司董事会 ? 对当期损益的影响：与收益相关的政府补助 5,111,049.20 元将计入 当期损益；最终对公司 2025 年损益的影响将以年度审计确认后的结 果为准。 一、获得政府补助的基本情况 称"公司"）及各下属子公司累计收到各类政府补助共计 5,111,049.20 元。 其中，与收益相关的政府补助 5,111,049.20 元,占公司最近一个会计年度经 审计净利润绝对值的 10.41%。 ...

（文章来源：证券日报） 证券日报网讯 7月31日晚间，司太立发布公告称，2025年1月1日至7月30日，公司及各下属子公司累计 收到各类政府补助共计5，111，049.20元。 ...

Core Viewpoint - The stock price of Sitaili reached 11.44 yuan as of July 31, 2025, reflecting a 3.53% increase from the previous trading day, indicating positive market sentiment towards the company [1] Company Performance - Sitaili specializes in the research, production, and sales of pharmaceutical raw materials and intermediates, with products covering various therapeutic areas including anti-infection, cardiovascular, and nervous system [1] - In Q1 2025, the company reported a revenue of 686 million yuan and a net profit of 14.34 million yuan, showcasing its operational performance [1] Government Subsidies - From January 1 to July 30, 2025, Sitaili and its subsidiaries received a total of 5.11 million yuan in government subsidies, with subsidies related to income accounting for 10.41% of the company's audited net profit for the most recent fiscal year [1] Market Activity - On July 31, 2025, the net inflow of main funds into Sitaili amounted to 24.37 million yuan, indicating strong investor interest [1]

2024年1至12月份，司太立的营业收入构成为：医药行业占比85.6%，其他业务占比14.34%，其他行业 占比0.06%。 （文章来源：每日经济新闻） 司太立（SH 603520，收盘价：11.44元）7月31日晚间发布公告称，2025年1月1日至7月30日，浙江司太 立制药股份有限公司及各下属子公司累计收到各类政府补助共计约511万元。 ...

Group 1 - The company Sital (603520.SH) announced that from January 1 to July 30, 2025, it and its subsidiaries received a total of government subsidies amounting to 5.111 million yuan [1] - The government subsidies related to income totaled 5.111 million yuan, which accounts for 10.41% of the company's audited net profit for the most recent fiscal year [1]